Pro-neurogenic compounds
This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.
1. A compound having formula (III):
wherein:
each of R 1 , R 2 , R 4 , R 5 , R 7 , and R 8 is independently selected from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkynyl, and cyclopropyl;
R 3 is selected from halo, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkynyl, cyclopropyl, —N 3 , and cyano;
R 6 is selected from hydrogen, halo, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkynyl, cyclopropyl, —N 3 , and cyano;
each of L 1 and L 2 is, independently, C 1 -C 3 alkylene, which is optionally substituted with from 1-2 independently selected R c ;
A is CR A1 R A2 , wherein one of R A1 and R A2 is halo, and the other of R A1 and R A2 is hydrogen or C 1 -C 3 alkyl;
Z is —NR 10 R 11 or —OR 12 or —S(O) n R 13 , wherein n is 0, 1, or 2;
each of R 10 and R 11 is independently selected from:
(a) hydrogen;
(b) C 6 -C 10 aryl that is optionally substituted with from 1-4 R b ; or
(c) heteroaryl containing from 5-14 ring atoms, wherein from 1-6 of the ring atoms is independently selected from N, NH, N(C 1 -C 3 alkyl), O, and S; and wherein said heteroaryl is optionally substituted with from 1-4 R b ;
wherein one of R 10 and R 11 is (b) or (c);
each of R 12 and R 13 is:
(i) C 6 -C 10 aryl that is optionally substituted with from 1-4 R b ; or
(ii) heteroaryl containing from 5-14 ring atoms, wherein from 1-6 of the ring atoms is independently selected from N, NH, N(C 1 -C 3 alkyl), O, and S; and wherein said heteroaryl is optionally substituted with from 1-4 R b ;
R b at each occurrence is independently selected from the substituents delineated in (aa) through (dd) below:
(aa) C 1 -C 6 alkoxy; C 1 -C 6 haloalkoxy; C 1 -C 6 thioalkoxy; C 1 -C 6 thiohaloalkoxy; —O—(CH 2 ) 1-3 —[O(CH 2 ) 1-3 ] 1-3 —H; C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —NHC(O)(C 1 -C 6 alkyl);
(bb) halo; hydroxyl; cyano; nitro; —NH 2 ; azido; sulfhydryl; C 2 -C 6 alkenyl; C 2 -C 6 alkynyl; —C(O)H; —C(O)(C 1 -C 6 alkyl); —C(O)(C 1 -C 6 haloalkyl); C(O)OH; —C(O)O(C 1 -C 6 alkyl); —C(O)NH 2 ; —C(O)NH(C 1 -C 6 alkyl); —C(O)N(C 1 -C 6 alkyl) 2 ; —SO 2 (C 1 -C 6 alkyl); —SO 2 NH 2 ; —SO 2 NH(C 1 -C 6 alkyl); —SO 2 N(C 1 -C 6 alkyl) 2 ;
(cc) C 3 -C 6 cycloalkyl or heterocyclyl containing from 5-6 ring atoms, wherein from 1-2 of the ring atoms of the heterocyclyl is independently selected from N, NH, N(C 1 -C 6 alkyl), NC(O)(C 1 -C 6 alkyl), O, and S; and
(dd) phenyl or heteroaryl containing from 5-6 ring atoms, wherein from 1-2 of the ring atoms of the heteroaryl is independently selected from N, NH, N(C 1 -C 3 alkyl), O, and S; wherein each of said phenyl and heteroaryl is optionally substituted with from 1-3 substituents independently selected from halo; hydroxyl; cyano; nitro; —NH 2 ; —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —NHC(O)(C 1 -C 6 alkyl), C 1 -C 6 alkoxy; C 1 -C 6 haloalkoxy; C 1 -C 6 thioalkoxy; C 1 -C 6 thiohaloalkoxy; C 1 -C 6 alkyl, and C 1 -C 6 haloalkyl;
and
R c at each occurrence is, independently selected from halo, C 1 -C 6 alkoxy, C 1 -C 6 thioalkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 thiohaloalkoxy, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —NHC(O)(C 1 -C 6 alkyl), and cyano;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein the carbon attached to R A1 and R A2 is substituted with four different substituents.
3. The compound of claim 2 , wherein the carbon attached to R A1 and R A2 is (R) configured.
4. The compound of claim 3 , wherein the (R) configured formula (III) compound is substantially free of a formula (III) compound that is S configured at the carbon atom attached to R A1 and R A2 .
5. The compound of claim 2 , wherein the carbon attached to R A1 and R A2 is (S) configured.
6. The compound of claim 4 , wherein the (S) configured formula (III) compound is substantially free of a formula (III) compound that is (R) configured at the carbon atom attached to R A1 and R A2 .
7. The compound of claim 2 , wherein the formula (III) compound is (+) (dextrorotatory).
8. The compound of claim 7 , wherein the (+) (dextrorotatory) compound is substantially free of a formula (III) compound that is (−) (levororotatory).
9. The compound of claim 2 , wherein the formula (III) compound is (−) (levororotatory).
10. The compound of claim 9 , wherein the (−) (levororotatory) compound is substantially free of a formula (III) compound that is (+) (dextrorotatory).
11. The compound of claim 1 , wherein R 3 is halo.
12. The compound of claim 1 , wherein R 3 is bromo.
13. The compound of claim 12 , wherein each of R 1 , R 2 , and R 4 is hydrogen.
14. The compound of claim 1 , wherein R 6 is selected from halo, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkynyl, cyclopropyl, —N 3 , and cyano.
15. The compound of claim 1 , wherein R 6 is halo or C 1 -C 6 alkyl.
16. The compound of claim 1 , wherein R 6 is halo.
17. The compound of claim 1 , wherein R 6 is bromo.
18. The compound of claim 17 , wherein each of R 5 , R 7 , and R 8 is hydrogen.
19. The compound of claim 1 , wherein Z is —NR 10 R 11 .
20. The compound of claim 19 , wherein one of R 10 and R 11 is:
(b) C 6 -C 10 aryl that is optionally substituted with from 1-4 R b ; or
(c) heteroaryl containing from 5-14 ring atoms, wherein from 1-6 of the ring atoms is independently selected from N, NH, N(C 1 -C 3 alkyl), O, and S; and wherein said heteroaryl is optionally substituted with from 1-4 R b ;
and the other of R 10 and R 11 is hydrogen.
21. The compound of claim 1 , wherein Z is —OR 12 .
22. The compound of claim 21 , wherein R 12 is C 6 -C 10 aryl that is optionally substituted with from 1-4 R b .
23. A pharmaceutical composition comprising a compound or salt of claim 1 and a pharmaceutically acceptable carrier.
24. A compound having formula (III):
wherein:
each of R 1 , R 2 , R 4 , R 5 , R 7 , and R 8 is independently selected from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkynyl, and cyclopropyl;
R 3 is selected from halo, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkynyl, cyclopropyl, —N 3 , and cyano;
R 6 is selected from hydrogen, halo, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkynyl, cyclopropyl, —N 3 , and cyano;
each of L 1 and L 2 is, independently, C 1 -C 3 alkylene, which is optionally substituted with from 1-2 independently selected R c ;
A is CR A1 R A2 , wherein one of R A1 and R A2 is halo or OR 9 , wherein R 9 is hydrogen or C 1 -C 3 alkyl that is optionally substituted with hydroxyl or C 1 -C 3 alkoxy, and the other of R A1 and R A2 is hydrogen or C 1 -C 3 alkyl;
Z is —OR 12 ;
R 12 is:
(i) C 6 -C 10 aryl that is optionally substituted with from 1-4 R b ; or
(ii) heteroaryl containing from 5-14 ring atoms, wherein from 1-6 of the ring atoms is independently selected from N, NH, N(C 1 -C 3 alkyl), O, and S; and wherein said heteroaryl is optionally substituted with from 1-4 R b ;
R b at each occurrence is independently selected from the substituents delineated in (aa) through (dd) below:
(aa) C 1 -C 6 alkoxy; C 1 -C 6 haloalkoxy; C 1 -C 6 thioalkoxy; C 1 -C 6 thiohaloalkoxy; —O—(CH 2 ) 1-3 —[O(CH 2 ) 1-3 ] 1-3 —H; C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl);
(bb) halo; hydroxyl; cyano; nitro; —NH 2 ; azido; sulfhydryl; C 2 -C 6 alkenyl; C 2 -C 6 alkynyl; —C(O)H; —C(O)(C 1 -C 6 alkyl); —C(O)(C 1 -C 6 haloalkyl); C(O)OH; —C(O)O(C 1 -C 6 alkyl); —C(O)NH 2 ; —C(O)NH(C 1 -C 6 alkyl); —C(O)N(C 1 -C 6 alkyl) 2 ; —SO 2 (C 1 -C 6 alkyl); —SO 2 NH 2 ; —SO 2 NH(C 1 -C 6 alkyl); —SO 2 N(C 1 -C 6 alkyl) 2 ;
(cc) C 3 -C 6 cycloalkyl or heterocyclyl containing from 5-6 ring atoms, wherein from 1-2 of the ring atoms of the heterocyclyl is independently selected from N, NH, N(C 1 -C 6 alkyl), NC(O)(C 1 -C 6 alkyl), O, and S; and
(dd) phenyl or heteroaryl containing from 5-6 ring atoms, wherein from 1-2 of the ring atoms of the heteroaryl is independently selected from N, NH, N(C 1 -C 3 alkyl), O, and S; wherein each of said phenyl and heteroaryl is optionally substituted with from 1-3 substituents independently selected from halo; hydroxyl; cyano; nitro; —NH 2 ; —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —NHC(O)(C 1 -C 6 alkyl), C 1 -C 6 alkoxy; C 1 -C 6 haloalkoxy; C 1 -C 6 thioalkoxy; C 1 -C 6 thiohaloalkoxy; C 1 -C 6 alkyl, and C 1 -C 6 haloalkyl;
and
R c at each occurrence is, independently selected from halo, C 1 -C 6 alkoxy, C 1 -C 6 thioalkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 thiohaloalkoxy, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , NHC(O)(C 1 -C 6 alkyl), and cyano;
or a pharmaceutically acceptable salt thereof.
25. The compound of claim 24 , wherein the carbon attached to R A1 and R A2 is substituted with four different substituents.
26. The compound of claim 25 , wherein the carbon attached to R A1 and R A2 is (R) configured.
27. The compound of claim 26 , wherein the (R) configured formula (III) compound is substantially free of a formula (III) compound that is S configured at the carbon atom attached to R A1 and R A2 .
28. The compound of claim 25 , wherein the carbon attached to R A1 and R A2 is (S) configured.
29. The compound of claim 28 , wherein the (S) configured formula (III) compound is substantially free of a formula (III) compound that is (R) configured at the carbon atom attached to R A1 and R A2 .
30. The compound of claim 25 , wherein the formula (III) compound is (+) (dextrorotatory).
31. The compound of claim 30 , wherein the (+) (dextrorotatory) compound is substantially free of a formula (III) compound that is (−) (levororotatory).
32. The compound of claim 25 , wherein the formula (III) compound is (−) (levororotatory).
33. The compound of claim 32 , wherein the (−) (levororotatory) compound is substantially free of a formula (III) compound that is (+) (dextrorotatory).
34. The compound of claim 24 , wherein R 3 is halo.
35. The compound of claim 24 , wherein R 3 is bromo.
36. The compound of claim 35 , wherein each of R 1 , R 2 , and R 4 is hydrogen.
37. The compound of claim 24 , wherein R 6 is selected from halo, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkynyl, cyclopropyl, —N 3 , and cyano.
38. The compound of claim 24 , wherein R 6 is halo or C 1 -C 6 alkyl.
39. The compound of claim 24 , wherein R 6 is halo.
40. The compound of claim 24 , wherein R 6 is bromo.
41. The compound of claim 40 , wherein each of R 5 , R 7 , and R 8 is hydrogen.
42. The compound of claim 24 , wherein R 12 is C 6 -C 10 aryl that is optionally substituted with from 1-4 R b .
43. A pharmaceutical composition comprising a compound or salt of claim 24 and a pharmaceutically acceptable carrier.